Physician profile

Tie Wei

Family Medicine · Bellevue, WA

NPI 1336264761

$2,397.93

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,081.71

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $640.00 2019
Novo Nordisk INC $451.43 2023-2024
Janssen Pharmaceuticals, INC $281.41 2022-2023 Xarelto
Astrazeneca Pharmaceuticals Lp $257.01 2022-2023 Farxiga
Phathom Pharmaceuticals, INC. $244.41 2024 Voquezna
Amgen INC. $146.56 2019-2020
Gilead Sciences, INC. $125.00 2019
Lilly USA, LLC $122.30 2024 Jardiance
Boehringer Ingelheim Pharmaceuticals, INC. $114.58 2021
Organogenesis INC. $15.23 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Tie Wei

$2,397.93

in general payments reported 2019-2025

Years
2019-2024
Top company
Novartis Pharmaceuticals Corporation

https://glasscript.com/doctor/60260/tie-wei

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.